Lv1
90 积分 2022-10-10 加入
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
3个月前
已完结
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
7个月前
已完结
Genetics of Atypical Hemolytic Uremic Syndrome (aHUS)
8个月前
已完结
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
9个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
9个月前
已完结
Ways to fit a PK model with some data below the quantification limit
9个月前
已完结
Handling Data Below the Limit of Quantification in Mixed Effect Models
9个月前
已完结
OP0025 FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY
9个月前
已完结
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
9个月前
已完结
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
9个月前
已完结
皖公网安备34019202002308
